Zai Lab Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Zai Lab stock.
View analyst ratings for Zai Lab or view top-rated stocks.

5 equities research analysts have issued 12 month price objectives for Zai Lab's stock. Their ZLAB stock forecasts range from $64.00 to $193.00. On average, they predict Zai Lab's share price to reach $117.50 in the next twelve months. This suggests a possible upside of 243.4% from the stock's current price.
View analysts' price targets for Zai Lab or view top-rated stocks among Wall Street analysts.

Zai Lab's stock was trading at $62.85 at the start of the year. Since then, ZLAB stock has decreased by 45.6% and is now trading at $34.22.
View the best growth stocks for 2022 here.

Zai Lab is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Zai Lab.

Zai Lab Limited (NASDAQ:ZLAB) released its earnings results on Tuesday, November, 9th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.24) by $0.23. The company earned $43.10 million during the quarter, compared to analysts' expectations of $42.43 million. Zai Lab had a negative trailing twelve-month return on equity of 37.26% and a negative net margin of 324.08%.
View Zai Lab's earnings history.

Zai Lab issued an update on its first quarter earnings guidance on Tuesday, May, 10th. The company provided EPS guidance of ($0.86) for the period, compared to the consensus EPS estimate of ($1.23). The company issued revenue guidance of $46.7 million, compared to the consensus revenue estimate of $45.72 million.

Some companies that are related to Zai Lab include Viatris (VTRS), Ono Pharmaceutical (OPHLF), United Therapeutics (UTHR), Biohaven Pharmaceutical (BHVN), Elanco Animal Health (ELAN), Jazz Pharmaceuticals (JAZZ), Dr. Reddy's Laboratories (RDY), Organon & Co. (OGN), Teva Pharmaceutical Industries (TEVA), Legend Biotech (LEGN), Grifols (GRFS), Maravai LifeSciences (MRVI), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS) and Perrigo (PRGO).
View all of ZLAB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

(ZLAB) raised $100 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Zai Lab's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Invesco Ltd. (8.57%), BlackRock Inc. (4.07%), Viking Global Investors LP (3.25%), Baillie Gifford & Co. (2.83%), Vanguard Group Inc. (2.34%) and Segantii Capital Management Ltd (2.34%). Company insiders that own Zai Lab stock include Harald Reinhart, John D Diekman, John D Diekman, Kai-Xian Chen, Peter Wirth, Tao Fu, William Ki Chul Cho, William Lis and Ying Du.
View institutional ownership trends for Zai Lab.

ZLAB stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Baillie Gifford & Co., Capital World Investors, Brilliance Asset Management Ltd., State Street Corp, Tree Line Advisors Hong Kong Ltd., JPMorgan Chase & Co., and Group One Trading L.P.. Company insiders that have sold Zai Lab company stock in the last two years include Harald Reinhart, John D Diekman, Kai-Xian Chen, Tao Fu, William Ki Chul Cho, William Lis, and Ying Du.
View insider buying and selling activity for Zai Lab or view top insider-selling stocks.

ZLAB stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Invesco Ltd., Capital International Investors, Segantii Capital Management Ltd, Genesis Investment Management LLP, Capital Group International Inc. CA , Woodline Partners LP, and Zeal Asset Management Ltd.
View insider buying and selling activity for Zai Lab or or view top insider-buying stocks.

Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ZLAB stock can currently be purchased for approximately $34.22.

Zai Lab (NASDAQ:ZLAB) has a market capitalization of $3.35 billion and generates $144.31 million in revenue each year. The company earns $-704.47 million in net income (profit) each year or ($5.87) on an earnings per share basis.

Zai Lab employs 1,951 workers across the globe.

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The official website for Zai Lab is www.zailaboratory.com. The company can be reached via phone at 862161632588, via email at [email protected], or via fax at 86-21-6163-2570.